My Article On Drug Discovery Approach Computer Aided Drug Design Cadd

Research in the pharmaceutical sciences and medicinal chemistry has taken an important new direction in the past two decades with a focus on large molecules, especially peptides and proteins, as well as DNA therapeutics. In Drug Design and Discovery: Methods and Protocols, leading experts provide an in-depth view of key protocols that are commonly used in drug discovery laboratories. Covering both classic and cutting-edge techniques, this volume explores computational docking, quantitative structure-activity relationship (QSA and proteins with fluorescent labels, DNA-microarray, zebrafish model for drug screening, and other analytical screening and biological assays that are routinely used during the drug discovery process. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Thorough and accessible, Drug Design and Discovery: M laboratory reference for pharmaceutical chemists, medicinal chemists, and pharmacologists as well as for molecular biologists.

Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety de personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.

Examines coordination of Federal LSD research programs. Focuses on LSD's alleged potential therapeutic effects.

Over 25 million people in the U.S. alone have benefited from statins--such drugs as Lipitor, Zocor, Crestor, Pravachol, and other cholesterol-lowering medicines--in preventing stroke, heart attack, and other forms of coronary heart disease. But how did these remarkable, life-saving drugs come into being? In Triumph of the Heart, Dr. Jie Jack Li, a medicinal chemist and expert on drug discovery, tells for the first time the fascinating story of statins. Drawn from discussions with many scientists involved in the discovery and development o human side of science by revealing the role played by persistence, luck, and sudden insight that characterize major discoveries. For scientists in the drug industry, health care professionals, students of medicine, and all those intrigued by the basic human drive to explore and discover, Triumph of the Heart offers a compelling view of one of the most important drug discoveries of our time.

Drug Design and Discovery

A Monthly Record of the Medical Auxiliary Sciences

Opportunities and Challenges in Medicinal Chemistry

Biomarkers in Drug Development

Basic Principles of Drug Discovery and Development

Drug Discovery and Development

Genomics in Drug Discovery and Development

Since 1987, Anyone Can Intubate has been the book for teaching intubation and related techniques. This 5th edition has been extensively rewritten and many new figures have been added. -- Provided by publisher.

The joint ages of friends Joy Lennick and Jean Wilson may add up to one hundred and seventy one years, but there's nothing "old lace" about these two women writers; while the "arsenic" connection is questionable... Both adept at delving into the messy, murky world of murder, it is enlightening, and sometimes, a relief... to discover their added light, humorous touch. This makes for a diverse selection of highly entertaining short stories to tickle the fancy of readers of a variety of genres. Jean Wilson worked as a Queen's Nurse in the 1950s, and soon earned the affectionate nickname 'The Angel of Aldgate' for her cheerful, hard work among the sick of the East End of London; and Joy Lennick wore a few hats before becoming an author in 1984; adding many writing projects to her long list, including five books.

Twelve years have elapsed since the appearance of the first volume and it is with great pleasure that the Editor is now able to present volume 15. During these twelve years various fields of drug research have undergone important, partly revolutionary, changes. A number of these have already been dealt with, so that the series PROGRESS IN DRUG RESEARCH contains a comprehensive review of a substantial part of our current knowledge. The Editor is particularly grateful for the opportunity of transmitting to those connected with the development of drugs the extensive knowledge of the Authors, who, without exception, are themselves actively engaged in research. Drug research is currently in a state of transformation: reconsideration in the light of the past and reorientation with a view to the future. To a large extent this is due to the tumultuous developments in the last 20 years, developments which are unparalleled in the history of medicine and the consequences of which cannot yet be completely evaluated. Unfortunately, however, the current situation is not devoid of its unpleasant and even tragic aspects, aspects which fall outside the research worker's sphere or influence. Those connected with drug research, be they in industry, in universities or in clinics, are aware of these problems, and, as a result of this awareness, are all the more in need of an aid which will assist them in ascertaining the current position and in fixing future goals.

Natural products hold a prominent position in the current discovery and development of drugs and have diverse indications for both human and animal health. Plants, in particular, play a leading role as a source of specialized metabolites with medical effects. Other organisms, such as marine and terrestrial animals and microorganisms, produce very important drug candidate molecules. Specialized metabolites from these varied natural sources can be used directly as bioactive compounds or drug precursors. In addition, due to their broad chemical diversity, they can act as drug prototypes and/or be used as pharmacological tools for different targets. Some examples of natural metabolites that have been developed into useful medical drug are cardiotonic digoxin from Digitalis sp., antimalarial artemisinin from Artemisia annua, anti-cancer taxol from Taxus sp., or podophyllotoxin from Podophyllum peltatum, which served as a synthetic model for the anti-cancer etoposide. The study of natural products is still attracting great scientific attention and their current importance, as a valuable lead for drug discovery, is undebatable. I cordially invite authors to contribute original articles, as well as survey articles, that give the readers of Molecules **MOLECULES NEEDS TO BE ITALICIZED** updated and new perspectives on natural products in drug discovery, including but not limited to natural sources, identification and separation of bioactive phytochemicals, standardization, new biological targets, pre-clinical and clinical trials, pharmacological effects/side effects, and bioassays.

A Guide for Medicinal Chemists and Pharmacologists

Bioactive Natural Products

The Author's True Story about Her Bout with Cancer

Where Angels & Devils Tread

Present and Future

Triumph of the Heart

Too Many Stories Not to Tell

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

An Internal Affairs detective pursues the vigilante cops who murdered his brother. Will he choose a love that cannot be consummated? Or will he choose guilt, vengeance and his own brand of vigilante justice?

Reviews cooperative efforts among Federal and international agencies responsible for medical research on experimental drugs and regulation of pharmaceutical industry marketing practices. Includes review of thalidomide marketing and use.

Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia.

Clinical, Scientific, Patient, and Caregiver Perspectives

Psychoeducational Assessment of Students who are Visually Impaired Or Blind

Vigilante Justice

Interagency Coordination in Drug Research and Regulation: The Bureau of Medicine in the Food and Drug Administration

Methods and Protocols

My Overdue Book

I Am Cancer Free

Increase your child's dental awareness by showing him/her that teeth have "emotions" too! Coloring introduces feelings, concepts and emotions quite well. It is an activity well-loved because of its many benefits, especially the formation of essential life skills like patience, determination control and self-confidence too. Control your child's fear of the dentist; grab a copy of this coloring book today!

Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].

The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians.

Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process. This book provides thoughtful and valuable discussions and analysis of the social challenges and potential opportunities through all stages of the pharmaceutical process, from inception through marketing. With a unique focus on the social factors that increasingly play a role in how drug development is planned, structured, and executed throughout the drug product lifecycle, this is an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society. Organized in a sequence of interrelated theories and principles that provide the foundation for increased understanding of the relevant social aspects Includes analysis of important new advances, key scientific and strategic issues, and overviews of recent progress in drug development Provides a global perspective with examples from developed areas, such as the US, Japan, Canada and Europe, as well as faster-growing and emerging economies including Brazil, Russia, India, and China Serves as an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society

Hearings ...

A Handbook of Practice, Application, and Strategy

Hearings Before the Subcommittee on Executive Reorganization ... 89-2, May 24-26, 1966

Hearings, Eighty-ninth Congress, Second Session

Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

Rare Disease Drug Development

Concepts and Applications

Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator ' s fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist ' s early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry

Bioactive natural products are a rich source of novel therapeutics. Thus, the search for bioactive molecules from nature continues to play an important role in fashioning new medicinal agents. This volume, which comprises sixteen chapters written by active researchers and leading experts in natural products chemistry, brings together an overview of current discoveries in this remarkable field. It also provides information on the industrial application of natural products for medicinal purposes. This book will serve as a valuable resource for researchers to predict promising leads for developing pharmaceuticals to treat various ailments and disease manifestations.

Discover how biomarkers can boost the success rate of drugdevelopment efforts As pharmaceutical companies struggle to improve the success rateand cost-effectiveness of the drug development process, biomarkershave emerged as a valuable tool. This book synthesizes and reviewsthe latest efforts to identify, develop, and integrate biomarkersas a key strategy in translational medicine and the drugdevelopment process. Filled with case studies, the bookdemonstrates how biomarkers can improve drug development timelines,lower costs, facilitate better compound selection, reducelate-stage attrition, and open the door to personalizedmedicine. Biomarkers in Drug Development is divided into eightparts: Part One offers an overview of biomarkers and their role in drugdevelopment. Part Two highlights important technologies to help researchersidentify new biomarkers. Part Three examines the characterization and validation processfor both drugs and diagnostics, and provides practical advice onappropriate statistical methods to ensure that biomarkers fulfilltheir intended purpose. Parts Four through Six examine the application of biomarkers indiscovery, preclinical safety assessment, clinical trials, andtranslational medicine. Part Seven focuses on lessons learned and the practical aspectsof implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including dataintegration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or moreleading experts, including scientists from biotechnology andpharmaceutical firms, academia, and the U.S. Food and DrugAdministration. Their contributions offer pharmaceutical andclinical researchers the most up-to-date understanding of thestrategies used for and applications of biomarkers in drugdevelopment.

"Alzheimer's Disease Drug Development: A Research and Development Ecosystem captures the complexity of Alzheimer's disease (AD) drug develop and provides a comprehensive set of perspectives from the many stakeholders involved in discovering and developing new therapies for AD. There is no greater unmet therapeutic need for humanity than effective therapies for brain disorders. The suffering caused by these conditions and other neurodegenerative disorders is overwhelming and is burdened with substantial stigma. Therefore, I have devoted my professional life to changing the way brain disorders such as schizophrenia, depression, AD, among others are not only treated, but also viewed by society. From my time with the National Institutes of Health, Janssen and Johnson & Johnson where I serve as the Global Head of Science for Minds, my colleagues and I recognize there is still much to uncover about brain disorders due to the rich complexity of the brain and the challenges in accessing it. But that is not a reason to stop - especially as we enter the golden age of neuroscience, driven largely by scientific breakthroughs and accelerated regulatory pathways"--

Pharmaceutical Biotechnology

Social Aspects of Drug Discovery, Development and Commercialization

Alzheimer's Disease Drug Development

The Calcutta Journal of Medicine

Exposing the Crisis of Credibility in Clinical Research

Organization and Coordination of Federal Drug Research and Regulatory Programs: LSD

Statistical Issues in Drug Development

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy. To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

Natural Products have been important sources of useful drugs from prehistoric times to the present. This book gives an overview about this field and provides important recent contributions to the discovery of new drugs generated by research on natural products. Total synthesis of natural products with interesting biological activities is paving the way for the preparation of new and improved analogs. The methods of combinatorial chemistry permit the selection of the best drug from a large number of candidates. Beyond synthesis and evaluation of organic molecules a number of new bioorganic methods are coming to the fore and will be discucced in this isue of the ERnst schering Research Foundation workshop proceedings.

My Overdue Book: Too many stories not to tell: spells out the varied episodes in the life of a man who spent decades working in Hollywood. He began as a little boy in Cincinnati impressed early on by the broadcasting magic of radio and then TV in the middle of twentieth century America. His drive to get into broadcasting culminates in an early success that gets interrupted by an unexpected sidebar in The US Army and a subsequent tour as an Infantryman in Vietnam in the late 1960's. His yearlong excursion in "Fun City East," with its repeated life and death experiences, had lifelong effects on this soldier-of-media. Following his wanderings through the jungles of Vietnam, Bright's interactions with many of America's top public figures throughout his decades in radio and television come to life with intriguing stories that are personal, professional, positive and negative. It's life without a filter! Readers across generations will share and co-experience numerous real life feelings and emotions with writer Bright as his winding trail of life opens in front of them. book endorsement for peter bright; i always thought that peter bright and i had many things in common; we both grew up in ohio, we both had careers in the live event and variety side of television, and the few times we had times to talk i thought we shared a mutual philosophy toward the ups and downs of life. but it wasn't until i read his "overdue" book that i realized just what a rich and storied life peter has had and how much more deeply he had experienced the highs and lows, particularly during his years in the military, than i ever could have imagined. it really amazes me just how little we know about people we think we know, and just how much more we appreciate who they are when we are fortunate enough to have that background filled in by someone as articulate and able to express both facts and feelings as peter has in this book. when i started to read it, i thought all of those common events that we shared would be an interesting parallel track to my life and as such i would have a great frame of reference, but as i read on, i realized just what an amazing story peter has to tell and just how well he tells it. ken ehrlich, executive producer, the grammy awards

This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R&D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.

The Role of Natural Products in Drug Discovery

Progress in Drug Research

A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care

The Core Model

Interagency Coordination in Drug Research and Regulation

The Illusion of Evidence-Based Medicine

The Looming Crisis in Drug Development

This is a most touching and emotional true story. of the author's battle with cancer.It is a detailed and personal account of how a very strong believer and family-oriented woman beat ovarian cancer. Although that type of cancer historically develops rapidly and has devastating effects, this true story shows how faith, family and love are a powerful force to reckon with. A must read for anyone with or without an illness! Eight years hence she is Cancer Free.It shows what faith in God can do. God is really alive and can work miracles in our lives. We just have to believe. The Author relates events when her life and financial well-being were threatened by this dreadful disease. Her strong faith in God saw her through all the trials she had to undergo during her several months of treatment. Writing this book gives her the opportunity to demonstrate to others the meaning of prayer and family unity . Eight years hence, she is now Cancer Free and wants to shout it to the world.The book serves as an inspiration for those in a similar situation to not give up but trust in god and continue fighting. She especially wants to acknowledge her loving husband who was a pillar of support throughout her ordeal.

Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes. Statistical Issues in Drug Development presents an essential and thought provoking guide to the statistical issues and controversies involved in drug development. This highly readable second edition has been updated to include: Comprehensive coverage of the design and interpretation of clinical trials. Expanded sections on missing data, equivalence, meta-analysis and dose finding. An examination of both Bayesian and frequentist methods. A new chapter on pharmacogenomics and expanded coverage of pharmaco-epidemiology and pharmaco-economics. Coverage of the ICH guidelines, in particular ICH E9, Statistical Principles for Clinical Trials. It is hoped that the book will stimulate dialogue between statisticians and life scientists working within the pharmaceutical industry. The accessible and wide-ranging coverage make it essential reading for both statisticians and non-statisticians working in the pharmaceutical industry, regulatory bodies and medical research institutes. There is also much to benefit undergraduate and postgraduate students whose courses include a medical statistics component.

Drug discovery and development process aims to make available medications that are safe and effective in improving the length and quality of life and relieving pain and suffering. However, the process is very complex, time consuming, resource intensive, requiring multi-disciplinary expertise and innovative approaches. There is a growing urgency to identify and develop more effective, efficient, and expedient ways to bring safe and effective products to the market. The drug discovery and development process relies on the utilization of relevant and robust tools, methods, models, and validated biomarkers that are predictive of clinical effects in terms of diagnosis, prevention, therapy, and prognosis. There is a growing emphasis on translational research, a bidirectional bench to the bedside approach, in an effort to improve the process efficiency and the need for further innovations. The authors in the book discuss the current and evolving state of drug discovery and development.

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry´ s productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. Explores the current state-of-the-art in the pharmaceutical industry and the global healthcare sector Includes insights from world-leading figures in the pharmaceutical industry, healthcare sector, federal funding agencies, regulatory bodies, investment sector, entrepreneurship, intellectual property law, philanthropic organizations, and advocacy groups Develops in-depth, original concepts, which have important implications in the understanding of, and search for, potential solutions to the world´ s health care crisis

A Prescription for Change

An Insider's Guide to the FDA's New Drug Approval Process, for Scientists, Investors, and Patients

The Story of Statins

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Natural Products and Drug Discovery

New Drugs

Research and Development Ecosystem

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine.

Drug development, the processes by which a chemical compound becomes a "drug" and is approved for sale by the FDA and European and Asian regulators, is not for the faint-of-heart or the shortsighted. Designing and monitoring studies, obtaining and analyzing scientific data, and reconciling clinical results against the ethical constraints and regulatory guidelines of government agencies, requires a complex interaction of in-house specialists and academic and commercial consultants worldwide. Scientific, technical, and tactical considerations play out in an environment where a balance must be struck between the often-competing interests of the corporation, its investors, government regulators, and the safety and well being of intended patients. All the while, dwindling patent protections impose an ever-contracting timeframe for success.Written to be accessible to a wide audience, NEW DRUGS provides a thorough, succinct, and practical understanding of these drug-development processes. If you're involved in the pharmaceutical industry, NEW DRUGS will provide scientific and management tools to increase the likelihood of regulatory approval at each phase of your compound's development. If you're a patient or consumer, NEW DRUGS will enable you to intelligently discuss medications with your health-care provider and empower you to make informed decisions at the pharmacy. If your portfolio, rather than your health, makes you an interested observer of the fortunes of this critical sector of the US economy, NEW DRUGS will help you to decode press releases and annual reports, so that you can recognize and invest in well-run companies with promising products.

Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products. introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students includes specific 'product category chapters' focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products. entire chapter devoted to the principles of genetic engineering and how these drugs are developed. includes numerous relevant case studies to enhance student understanding no prior knowledge of protein structure is assumed

Modern Methods of Clinical Investigation

Artificial Intelligence in Drug Discovery

Infancy Through High School
My Pearly Whites (A Coloring Book for Children)
Evaluation of Enzyme Inhibitors in Drug Discovery
Interagency Coordination in Drug Research and Regulations
Organization and Coordination of Federal Drug Research and Regulatory Programs: LSD.